- Home
- PKBK vs FHTX Comparison
PKBK vs FHTX Comparison
Compare PKBK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PKBK | FHTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 247.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PKBK | FHTX |
|---|---|---|
| Price | $24.83 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.86 |
| AVG Volume (30 Days) | 24.1K | ★ 191.9K |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 21.56 | N/A |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $71,766,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $47.50 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.48 | ★ N/A |
| Revenue Growth | ★ 13.64 | N/A |
| 52 Week Low | $16.94 | $2.95 |
| 52 Week High | $24.97 | $6.79 |
Technical Indicators
Market Signals| Indicator | PKBK | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 80.17 | 49.14 |
| Support Level | $23.72 | $4.33 |
| Resistance Level | $24.11 | $4.82 |
| Average True Range (ATR) | 0.55 | 0.30 |
| MACD | 0.18 | -0.03 |
| Stochastic Oscillator | 96.24 | 21.43 |
Price Performance
Historical ComparisonAbout PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.